These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22901567)

  • 41. Comparison of biochemical failure definitions for permanent prostate brachytherapy.
    Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Zelefsky MJ; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1487-93. PubMed ID: 16750326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer.
    Gestaut MM; Cai W; Vyas S; Patel BJ; Hasan SA; MunozMaldonado Y; Deb N; Swanson G
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):101-107. PubMed ID: 28586945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Definition of biochemical success following primary whole gland prostate cryoablation.
    Levy DA; Ross AE; ElShafei A; Krishnan N; Hatem A; Jones JS
    J Urol; 2014 Nov; 192(5):1380-4. PubMed ID: 24813344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy.
    Hinnen KA; Monninkhof EM; Battermann JJ; van Roermund JG; Frank SJ; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):883-8. PubMed ID: 21300477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.
    Kestin LL; Goldstein NS; Vicini FA; Mitchell C; Gustafson GS; Stromberg JS; Chen PY; Martinez AA
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):107-18. PubMed ID: 12182980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
    Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
    Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
    Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
    Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
    Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High dose brachytherapy as monotherapy for intermediate risk prostate cancer.
    Rogers CL; Alder SC; Rogers RL; Hopkins SA; Platt ML; Childs LC; Crouch RH; Hansen RS; Hayes JK
    J Urol; 2012 Jan; 187(1):109-16. PubMed ID: 22088340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.
    Crook JM; Bahadur YA; Bociek RG; Perry GA; Robertson SJ; Esche BA
    Cancer; 1997 Jan; 79(2):328-36. PubMed ID: 9010106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical control and toxicity for favorable- and intermediate-risk patients using real-time intraoperative inverse optimization prostate seed implant: Less is more!
    Shukla G; Sarkar A; Hanlon A; Crockett E; Chen HC; Martelli-Raben J; Glick A; Benge B; Lobis M; Terranova S; Desperito T; Cozzolino D; Kemmerer E; Mourtada F; Raben A
    Brachytherapy; 2017; 16(3):490-496. PubMed ID: 28185762
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
    Rossi PJ; Urbanic J; Clark PE; McCullough DL; Lee WR
    Brachytherapy; 2008; 7(4):286-9. PubMed ID: 18928924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy.
    Benzaquen D; Delouya G; Ménard C; Barkati M; Taussky D
    Brachytherapy; 2017; 16(2):348-352. PubMed ID: 28143764
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Cancer J; 2001; 7(5):404-12. PubMed ID: 11693899
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Kinetics differences between PSA bounce and biochemical failure in patients treated with 125I prostate brachytherapy.
    Kanzaki H; Kataoka M; Nishikawa A; Uwatsu K; Nagasaki K; Nishijima N; Hashine K
    Jpn J Clin Oncol; 2015 Jul; 45(7):688-94. PubMed ID: 25888709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.